Here's an academic-style abstract inspired by the provided summary and keywords, suitable for a medical research context and reflecting a 2023 timeframe:

**Abstract**

The management of stage IV metastatic breast cancer continues to evolve, as evidenced by recent updates detailed in the NCCN Guidelines Insights, Version 4.2023. This report underscores the expanding therapeutic options available to patients, contributing to observed improvements in survival outcomes. Contemporary recommendations prioritize personalized systemic therapy approaches, integrating targeted agents, immunotherapies, and endocrine therapies based on tumor biology and patient characteristics. The revisions reflect a growing understanding of resistance mechanisms and the potential for sequential or combination strategies. This document serves as a valuable resource for clinicians navigating the complexities of advanced breast cancer treatment, facilitating evidence-based decision-making within the dynamic landscape of stage IV disease.